Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Würselen – page 25

1 367 clinical trials in Würselen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Würselen at a glance
1 367
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 367 trials in Würselen

Open in trial search

Study of Trastuzumab Deruxtecan and Rilvegostomig for Patients with Advanced HER2-positive Biliary Tract Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:AstraZeneca AB

Study on Rilzabrutinib for Patients Aged 10-65 with Sickle Cell Disease

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Rilzabrutinib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Ovarian cancer

Recruiting

Study Comparing Rinatabart Sesutecan with Other Treatments for Patients with Platinum-Resistant Ovarian Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Genmab A/S

Breast cancer+3

Recruiting

Study on the Safety and Effectiveness of Capivasertib and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer After Hormone Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib
  • Sponsor:WSG Women's Cancer Study Group GmbH

Study of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) to Reduce Disease Flare-ups

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:AstraZeneca AB

Endometrial cancer+3

Recruiting

Study of Relacorilant, Nab-Paclitaxel, and Bevacizumab for Patients with Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Corcept Therapeutics Inc.

Study of ENTR-601-45 Safety and Effectiveness in Patients with Duchenne Muscular Dystrophy Who Can Skip Exon 45

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:ENTR-601-45
  • Sponsor:Entrada Therapeutics Inc.

Study Comparing Zilovertamab Vedotin with Drug Combination for Untreated Patients with Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Merck Sharp & Dohme LLC

Study of clopidogrel and acetylsalicylic acid (aspirin) for prevention of cardiovascular events in patients who survived intracerebral hemorrhage stroke

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:University Of Edinburgh

Gastric cancer

Recruiting

Study on [18F]-AlF-FAPI-74 for Staging Advanced Stomach Cancer in Patients Using PET/CT and Laparoscopy

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:[Al[18F]F]Fapi-74
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Study of elranatamab and lenalidomide combination versus standard chemotherapy and transplant in newly diagnosed multiple myeloma patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Intergroupe Francophone Du Myelome

Study of ENTR-601-44 in Children with Duchenne Muscular Dystrophy Who Are Eligible for Exon 44 Skipping Treatment

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:ENTR-601-44
  • Sponsor:Entrada Therapeutics Inc.

Other cities in Germany

The busiest research cities in the country

All 503 cities in Germany

Clinical research in Würselen

What the registry says about research in the country

01 Urological Oncology

Innovative research focusing on non-muscle invasive bladder cancer, evaluating combination therapies including immunotherapy approaches. These trials aim to improve treatment outcomes and reduce recurrence rates.

  • BCG Combination Therapy
  • Novel Immunotherapy Approaches
  • Disease-Free Survival Studies

Examining alternative treatment options including natural compounds for bladder cancer management.

02 Hematologic Disorders

Advanced research into polycythemia vera treatment resistance, utilizing artificial intelligence to predict therapeutic outcomes. Studies focus on optimizing hydroxyurea treatment protocols.

  • AI-Driven Treatment Prediction
  • Drug Resistance Analysis
  • Personalized Medicine Approaches

Integration of machine learning technologies to enhance treatment effectiveness.

03 Prostate Cancer Research

Comparative studies evaluating different dosing regimens for metastatic prostate cancer treatments, focusing on optimizing therapeutic combinations while minimizing adverse effects.

  • Treatment Safety Profiles
  • Dosing Schedule Optimization
  • Combination Therapy Assessment

Investigating innovative approaches to enhance treatment tolerability and effectiveness.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.